6don MSN
Sana Biotechnology showcases successful in vivo gene editing of stem cells in Nature publication
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...
On Monday, April 24, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in neurobiology and cognition. The Dart/NYU ...
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...
NEW YORK, March 15, 2007 -- On Monday, March 26, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in biomedical ...
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...
UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...
Application of ZFN Technology in Stem Cells has Potential to Yield High Value Research Reagents and Therapeutic Products ST. LOUIS and RICHMOND, Calif., Oct. 29 -- Sigma-Aldrich Corporation and ...
In RIT’s biotechnology bachelor’s degree you’ll develop technologies for genetics, agriculture, pharmaceuticals, vaccine development, energy/ environment, forensics, and more. Hands on Experience: ...
Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...
CHICAGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results